---
layout: default
title: Apis Mellifera Arctostaphylos Uva-Ursi Leaf Atropa
parent: 僅模型預測 (L5)
nav_order: 386
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Arctostaphylos Uva-Ursi Leaf Atropa
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Herbal/Homeopathic Formula: No TxGNN Repurposing Predictions Available

## One-Sentence Summary

This product is a complex 23-ingredient herbal and homeopathic formula containing ingredients classically associated with urinary tract conditions (e.g., Arctostaphylos uva-ursi, Equisetum hyemale, Sandalwood oil, Cantharis). The TxGNN model was unable to generate repurposing predictions, as no DrugBank ID could be resolved for this multi-ingredient combination. No supporting clinical trial or literature evidence was retrieved.

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established — no regulatory approval on record |
| Predicted New Indication | None — TxGNN did not return predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; in this case, not even a prediction) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this product. The pipeline could not resolve a DrugBank ID for the multi-ingredient string, which is required to anchor the drug node in the knowledge graph. Without a recognized drug entity, neither the knowledge-graph method nor the deep-learning model could produce candidate disease pairings.

From a pharmacological standpoint, the 23 listed ingredients span bee venom (*Apis mellifera*), anticholinergics (*Atropa belladonna*), botanical diuretics/urinary antiseptics (bearberry leaf, parsley, pumpkin flower, cubeb pepper, sandalwood oil, turpentine oil, watermelon seed), immunomodulators (*Echinacea angustifolia*), and classical homeopathic preparations (Causticum, ferrosoferric phosphate, silver nitrate). The ingredient profile is broadly consistent with traditional urinary tract formulations, but this is a clinical/ethnopharmacological inference—not a model output.

Because this is a combination product rather than a single chemical entity, standard repurposing methodology (which maps one drug to one or more diseases via shared mechanism or target) does not apply without first decomposing the formula into individually mappable components.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## US Market Information

This product has no US FDA approval on record and no license filings were retrieved.

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on individual ingredients:** Several components carry well-known safety signals that would require evaluation if this product were to be studied formally:
> - *Atropa belladonna* — anticholinergic toxicity risk; narrow therapeutic index
> - *Lytta vesicatoria* (Spanish fly / Cantharis) — nephrotoxic and caustic at elevated doses
> - *Macropiper methysticum* (Kava root) — hepatotoxicity warnings in multiple jurisdictions
> - Silver nitrate — caustic; mucosal irritant
> - Turpentine oil — renal and CNS toxicity at high doses

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline could not process this product because it is a multi-ingredient combination formula with no resolvable DrugBank ID. Without a machine-readable drug entity, no repurposing prediction can be generated, and no regulatory or safety baseline exists to evaluate.

**To proceed, the following is needed:**

1. **Decompose the formula** — Evaluate each of the 23 active ingredients individually; map each to its DrugBank entry to enable independent TxGNN predictions.
2. **Identify the lead active ingredient(s)** — Determine which component(s) drive the primary pharmacological effect; prioritize those for repurposing analysis.
3. **Retrieve MOA data per ingredient** — Query DrugBank API for mechanism of action, targets, and pharmacokinetics for each resolved component.
4. **Obtain package insert / regulatory filing** — Confirm the original approved indication (if any) and retrieve full warning/contraindication data.
5. **Reassess as individual drug candidates** — Once decomposed, resubmit each lead ingredient as a separate Evidence Pack entry for proper TxGNN evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

